SPRB
Closed
Spruce Biosciences inc
0.0711
-0.0014 (-1.93%)
Last Update: 01 Jul 2025 21:24:00
Yesterday: 0.0725
Day's Range: 0.07 - 0.0739
Send
sign up or login to leave a comment!
When Written:
2.02
Spruce Biosciences Inc. is a clinical-stage biotechnology company that is focused on developing and commercializing novel therapies for rare endocrine disorders. The company's lead product candidate, tildacerfont, is a selective antagonist of the corticotropin-releasing factor receptor type 1 (CRF1), which is being developed for the treatment of congenital adrenal hyperplasia (CAH), a rare genetic disorder that affects the adrenal glands.
Spruce Biosciences was founded in 2014 and is headquartered in Daly City, California. The company's mission is to improve the lives of patients with rare endocrine disorders by developing innovative therapies that address the underlying biology of these diseases.
In addition to tildacerfont, Spruce Biosciences has a pipeline of other product candidates in preclinical development for the treatment of other rare endocrine disorders. The company has raised over $170 million in funding from investors, including Omega Funds, Abingworth, and 5AM Ventures.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Spruce Biosciences was founded in 2014 and is headquartered in Daly City, California. The company's mission is to improve the lives of patients with rare endocrine disorders by developing innovative therapies that address the underlying biology of these diseases.
In addition to tildacerfont, Spruce Biosciences has a pipeline of other product candidates in preclinical development for the treatment of other rare endocrine disorders. The company has raised over $170 million in funding from investors, including Omega Funds, Abingworth, and 5AM Ventures.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








